ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2367

Acceptance Rate and Sociological Factors Involved in the Switch from Originator to Biosimilar Etanercept (SB4)

Marc Scherlinger1,2,3, Vincent Germain1, Emmanuel Langlois4 and Thierry Schaeverbeke5, 1Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, 2FHU ACRONIM, Bordeaux, France, 3Rheumatology, UMR CNRS 5164 - Immunoconcept, France, Bordeaux, France, 4CNRS-UMR 5116 Centre Emile Durkheim, Bordeaux, France, 5Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biosimilars, health behaviors and patient preferences

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Biosimilars represent major potential savings while preserving treatment quality. However, few data are known on how to address the switch from originator to biosimilar in outpatient settings. Our aim was to study acceptance rate and factors influencing acceptance of the switch from originator etanercept (Enbrel©) to biosimilar etanercept (SB4, Bénépali©) in patients with rheumatic disease.

Methods: Patients with a well-controlled rheumatic disease consulting in our rheumatology department were offered the switch for SB4. After oral and written information concerning biosimilar, free choice to accept the switch was left to the patients. The main outcome was primary switch acceptance rate defined by switch acceptance during the initial consult. Real switch adherence, socio-cultural factors and beliefs influencing switch acceptance rate were retrieved during a telephonic interview at distance from the consultation.

Results: Fifty-two patients were eligible for the switch: 32 (62%) with spondyloarthritis and 20 (38%) with rheumatoid arthritis. At the time of the consult, the primary acceptance rate was 92% (48/52). Patients refusing the switch were more likely to report a bad opinion on generic drugs (100% vs 11%, p < 0.001). Other patient characteristics were roughly identical except for a statistical trend in the refusal group toward older age (61.4 vs 50.7 years, p = 0.08) and longer disease duration (26 vs 12.1 years, p = 0.05). Despite initial acceptance, two patients did not begin SB4 after receiving negative information by their regular pharmacist. Real SB4 switch rate (defined as biosimilar use) was 85% (44/52) and 86% (38/44) of patients reported a good experience of the switch.

Conclusion:

When presented with positive and reassuring information, most patients agree to the switch from originator to biosimilar etanercept. Patient information, physician and pharmacist knowledge on biosimilars should be addressed in order to improve their diffusion.


Disclosure: M. Scherlinger, None; V. Germain, None; E. Langlois, None; T. Schaeverbeke, Pfizer, Inc., 2, 5,UCB, Inc., 5,Amgen Inc., 5,AbbVie Inc., 5,Janssen, 5,Roche, 5,BMS, 5,MSD, 5,Novartis, 5.

To cite this abstract in AMA style:

Scherlinger M, Germain V, Langlois E, Schaeverbeke T. Acceptance Rate and Sociological Factors Involved in the Switch from Originator to Biosimilar Etanercept (SB4) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/acceptance-rate-and-sociological-factors-involved-in-the-switch-from-originator-to-biosimilar-etanercept-sb4/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acceptance-rate-and-sociological-factors-involved-in-the-switch-from-originator-to-biosimilar-etanercept-sb4/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology